Prometheus Biosciences Stock Price To Book
| RXDXDelisted Stock | USD 199.92 0.24 0.12% |
Prometheus Biosciences fundamentals help investors to digest information that contributes to Prometheus Biosciences' financial success or failures. It also enables traders to predict the movement of Prometheus Stock. The fundamental analysis module provides a way to measure Prometheus Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Prometheus Biosciences stock.
Prometheus |
Prometheus Biosciences Company Price To Book Analysis
Prometheus Biosciences' Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Current Prometheus Biosciences Price To Book | 19.88 X |
Most of Prometheus Biosciences' fundamental indicators, such as Price To Book, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Prometheus Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
CompetitionBased on the latest financial disclosure, Prometheus Biosciences has a Price To Book of 19.8767 times. This is 22.6% lower than that of the Biotechnology sector and 229.08% higher than that of the Health Care industry. The price to book for all United States stocks is 109.01% lower than that of the firm.
Prometheus Price To Book Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Prometheus Biosciences' direct or indirect competition against its Price To Book to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Prometheus Biosciences could also be used in its relative valuation, which is a method of valuing Prometheus Biosciences by comparing valuation metrics of similar companies.Prometheus Biosciences is currently under evaluation in price to book category among its peers.
Prometheus Fundamentals
| Return On Equity | -0.33 | |||
| Return On Asset | -0.2 | |||
| Operating Margin | (40.65) % | |||
| Current Valuation | 4.39 B | |||
| Shares Outstanding | 47.81 M | |||
| Shares Owned By Insiders | 16.61 % | |||
| Shares Owned By Institutions | 81.01 % | |||
| Number Of Shares Shorted | 4.68 M | |||
| Price To Earning | (5.66) X | |||
| Price To Book | 19.88 X | |||
| Price To Sales | 627.82 X | |||
| Revenue | 6.81 M | |||
| Gross Profit | (106.04 M) | |||
| EBITDA | (145.78 M) | |||
| Net Income | (141.75 M) | |||
| Cash And Equivalents | 95.96 M | |||
| Cash Per Share | 2.35 X | |||
| Total Debt | 14.76 M | |||
| Debt To Equity | 0.08 % | |||
| Current Ratio | 13.32 X | |||
| Book Value Per Share | 14.62 X | |||
| Cash Flow From Operations | (123.25 M) | |||
| Short Ratio | 3.97 X | |||
| Earnings Per Share | (3.54) X | |||
| Target Price | 190.0 | |||
| Number Of Employees | 97 | |||
| Beta | -0.49 | |||
| Market Capitalization | 9.56 B | |||
| Total Asset | 740.77 M | |||
| Retained Earnings | (331.09 M) | |||
| Working Capital | 685.33 M | |||
| Current Asset | 135.99 M | |||
| Current Liabilities | 24.54 M | |||
| Net Asset | 740.77 M |
About Prometheus Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Prometheus Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Prometheus Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Prometheus Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Other Consideration for investing in Prometheus Stock
If you are still planning to invest in Prometheus Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Prometheus Biosciences' history and understand the potential risks before investing.
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |